Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...